Table 5.
Effect (%) of gliclazide MR minitablets on the plasma glucose levela in normal and STZ- treated rats
| Group |
Time (h)
|
|||||||
|---|---|---|---|---|---|---|---|---|
| 0 b | 1 | 2 | 4 | 6 | 8 | |||
| Normal rats (Control group) |
107.63±4.34 (100%) |
- | 129.63±9.24 (120.79±12.13%) |
132.50±8.02 (123.38±10.42%) |
127.38±8.31 (118.63±10.67%) |
126.13±7.28 (117.41±9.15%) |
||
| IR formulation | 112.43±7.25 (100%) |
58.86±3.98 (52.56±5,35%) |
59.86±14.71 (53.02±11.08%) |
87.29±13.16 (77.49±9.28%) |
90.00±18.79 (79.69±13.40%) |
90.57±21.69 (80.18±16.31%) |
||
| STZ-treated rats (Control group) |
115.43±8.92 (100%) |
- | 131,.1±19.27 (114.59±17.78%) |
140.71±19.81 (122.19±16.96%) |
157.00±28.34 (137.01±26.92%) |
150.29±30.32 (130.24±24.33%) |
||
| IR formulation | 114.57±5.74 (100%) |
83.1±16.96 (72.86±12.69%) |
87.14±10.02 (76.07±7.79%) |
95.00±6.88 (82.86±2.91%) |
101.00±12.11 (87.97±7.24%) |
109.00±19.79 (94.72±13.35%) |
||
a Plasma glucose levels are expressed as mg/dL
b Initial values of glucose blood concentration before gliclazide administration are considered as to 100%
the mean ± standard deviation (n = 7)
c Statistical significance at p < 0.05 (compared to the control group)